Association of two <i>BRM</i> promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis
Min Joon Lee(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), Nathan Kuehne(University Health Network), Daniel Shepshelovich(Columbia University Irving Medical Center), Dangxiao Cheng(Ontario Institute for Cancer Research), M. Catherine Brown(University Health Network), Katrina Hueniken(Centre for Addiction and Mental Health), Marc de Perrot(University Health Network), Shermi Liang(University of Florida Health), Lawson Eng(Princess Margaret Cancer Centre), David Reisman(University of Vermont Medical Center), Jeffrey P. Bruce(University Health Network), Zhuo Chen(Fujian Institute of Research on the Structure of Matter), Wei Xu(University Health Network), John Cho(University Health Network), Michael Herman(Borland Groover Clinic), Mindy Liang(University Health Network), Devalben Patel(University Health Network), Hadas Sorotsky(University Health Network), Penelope A. Bradbury(University Health Network), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 1
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k